Kyowa Hakko Kirin’s POTELIGEO Injection approved for PTCL and CTCL in Japan
Mogamulizumab, which is branded as ‘POTELIGEO Injection’, is a novel, humanized monoclonal antibody directed against CC chemokine receptor 4 (CCR4), which is over-expressed on various malignant T cells,